Neurotensin Receptor-1 Expression in Human Prostate Cancer: A Pilot Study on Primary Tumors and Lymph Node Metastases.
Blotting, Western
HT29 Cells
Humans
In Vitro Techniques
Lymphatic Metastasis
/ pathology
Male
Microscopy, Confocal
Neuropeptides
/ metabolism
PC-3 Cells
Prostate
/ metabolism
Prostatic Hyperplasia
/ metabolism
Prostatic Neoplasms
/ metabolism
Receptors, Neurotensin
/ metabolism
Xenograft Model Antitumor Assays
NTR1
neuropeptide
neurotensin receptor-1
prostate cancer
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
07 Apr 2019
07 Apr 2019
Historique:
received:
01
03
2019
revised:
27
03
2019
accepted:
01
04
2019
entrez:
10
4
2019
pubmed:
10
4
2019
medline:
28
7
2019
Statut:
epublish
Résumé
Neurotensin and its high-affinity receptor, NTR₁, are involved in the growth of various tumors. Few data are available regarding NTR₁ expression in normal and tumoral human prostate tissue samples. NTR₁ expression was assessed using immunohistochemistry in 12 normal prostate tissues, 11 benign prostatic hyperplasia (BPH), 44 prostate cancers, and 15 related metastatic lymph nodes (one per patient, when available). NTR₁-staining was negative in normal prostate and BPH samples. NTR₁ was overexpressed in four out of 44 (9.1%) primary tumors. There was no clear association between NTR₁ overexpression and age, PSA-values, Gleason score, pT-status, nodal-status, or margin. NTR₁ was expressed at a high level of five out of 15 (33.3%) metastatic lymph nodes. NTR₁ overexpression was thus more frequent in metastatic lymph nodes than in primary tumors (
Identifiants
pubmed: 30959962
pii: ijms20071721
doi: 10.3390/ijms20071721
pmc: PMC6479796
pii:
doi:
Substances chimiques
Neuropeptides
0
Receptors, Neurotensin
0
neurotensin type 1 receptor
0
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : TRAIL
ID : ANR-10-LABX-57
Références
Anticancer Res. 2003 Jan-Feb;23(1A):187-94
pubmed: 12680211
J Biol Chem. 2004 Mar 26;279(13):12636-46
pubmed: 14699144
Regul Pept. 2004 Aug 15;120(1-3):155-66
pubmed: 15177934
Carcinogenesis. 2006 Apr;27(4):708-16
pubmed: 16299383
Cancer Res. 2006 Jun 15;66(12):6243-9
pubmed: 16778199
Oncogene. 2007 Feb 1;26(5):745-56
pubmed: 16862179
Prostate. 2007 Feb 1;67(2):190-202
pubmed: 17044078
Biochem Biophys Res Commun. 2010 Jan 1;391(1):1007-13
pubmed: 19968961
Cancer Res. 2010 Jan 1;70(1):347-56
pubmed: 20048080
Clin Cancer Res. 2010 Sep 1;16(17):4401-10
pubmed: 20810387
Prostate. 2012 Apr;72(5):523-32
pubmed: 21748756
Cancer Res. 2011 Nov 1;71(21):6817-26
pubmed: 21903767
Prostate. 2013 Jun;73(8):801-12
pubmed: 23192379
Endocrine. 2014 Dec;47(3):659-61
pubmed: 24913418
J Nucl Med. 2014 Oct;55(10):1650-7
pubmed: 25189338
Lab Invest. 2015 Mar;95(3):283-95
pubmed: 25581609
Bioorg Med Chem. 2015 Jul 15;23(14):4026-33
pubmed: 25691211
EJNMMI Res. 2015 Mar 24;5:17
pubmed: 25859423
Oncotarget. 2016 Jan 5;7(1):193-208
pubmed: 26506594
J Med Chem. 2016 Jul 14;59(13):6480-92
pubmed: 27336295
Oncotarget. 2016 Oct 25;7(43):70303-70322
pubmed: 27611941
J Nucl Med. 2017 Jun;58(6):936-941
pubmed: 28254866
J Nucl Med. 2018 Feb;59(2):238-243
pubmed: 28775203
Mol Imaging. 2017 Jan-Dec;16:1536012117711369
pubmed: 28849698
J Nucl Med. 2018 May;59(5):809-814
pubmed: 29025990
Front Oncol. 2018 Jan 18;8:2
pubmed: 29404276
Lancet Oncol. 2018 Jun;19(6):825-833
pubmed: 29752180
Endocr Relat Cancer. 2018 Oct 1;26(2):131-146
pubmed: 30400059
Front Surg. 2018 Dec 07;5:74
pubmed: 30581819
Oncogene. 2019 Feb 15;:null
pubmed: 30770901
Proc Natl Acad Sci U S A. 1994 May 24;91(11):4673-7
pubmed: 8197117